Therapeutic Plasma Exchange Market

Therapeutic Plasma Exchange Market (Disease Indication: Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, and Others) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast, 2023-2031

Therapeutic Plasma Exchange Market Outlook 2031

  • The global industry was valued at US$ 1.5 Bn in 2022
  • It is estimated to grow at a CAGR of 7.5% from 2023 to 2031 and reach US$ 2.9 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of chronic diseases is fueling the therapeutic plasma exchange market size. Therapeutic Plasma Exchange (TPE) is gaining traction for the treatment of autoimmune diseases and neurological disorders as it helps remove large amounts of disease-causing agents that attack the body and cause symptoms.

Emergence of COVID-19 is likely to offer lucrative opportunities to players in the global therapeutic plasma exchange industry. Vendors are providing customizable solutions that can be adapted to different patient needs and treatment protocols. They are also developing advanced polymeric materials for use in membrane separation systems in plasmapheresis machines.

Therapeutic Plasma Exchange Market

Market Introduction

Therapeutic Plasma Exchange (TPE) is a procedure used for the treatment of various neurological disorders, renal disorders, hematology disorders, and metabolic disorders. In the procedure, an apheresis machine is used to remove and discard the filtered plasma and reinfused with red blood cells and fluids such as plasma or albumin. This process is also called plasmapheresis and is employed in the treatment of various chronic diseases such as Multiple Sclerosis (MS), myasthenia gravis, Guillain-Barré syndrome, cryoglobulinemia, and thrombotic thrombocytopenic purpura.

TPE focuses on removing various agents in the plasma, such as an antibody, toxin, or abnormal protein, that are causing the clinical symptoms of a disease. Patient experiences and outcomes with therapeutic plasma exchange therapy can vary widely depending on the underlying condition being treated. Technological advancements have led to the availability of upgraded apheresis machines that help remove pathological components in the blood. New single-door platelet and plasma machines extract 500 ml plasma directly from the donor whereas in a normal process of plasma extraction, 350 to 400 ml blood is collected.

Rise in Prevalence of Chronic Diseases Fueling Therapeutic Plasma Exchange Market Value

TPE is used for the treatment of various chronic diseases. It is employed to eliminate higher molecular weight substances, such as immunoglobulins or immune complexes, from plasma. TPE is recommended for the treatment of post-renal transplant rejection, anti-glomerular basement membrane (GBM) disease, Wegener's granulomatosis, and other renal diseases.

High incidence of chronic diseases is propelling the therapeutic plasma exchange market development. According to the paper ‘Incidence, Risk Factors, Treatment, and Consequences of Antibody-mediated Kidney Transplant Rejection: A Systematic Review, published in the journal PubMed in 2021, the incidence of Acute Antibody-mediated Kidney Transplant Rejection was 1.1%-21.5%. Antibody-mediated rejection is common and associated with an increased risk of death-censored graft failure.

Increasing prevalence of autoimmune diseases and neurological disorders is projected to spur the therapeutic plasma exchange market growth in the near future. TPE is widely utilized in the treatment of autoimmune diseases. It helps remove large amounts of disease-causing agents that attack the body and cause symptoms. TPE is typically employed alone or in conjunction with other treatment options such as intravenous immunoglobulins (IVIG) and corticosteroids.

TPE is effective in the treatment of MS. It removes proteins that attack tissues in the body. These proteins are found in blood plasma. According to the paper, ‘Rising Prevalence of Multiple Sclerosis Worldwide: Insights from The Atlas of MS, Third Edition, published in 2020, a total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population).

R&D in Therapeutic Plasma Exchange Driving Therapeutic Plasma Exchange Market Progress

Various studies are investigating the use of TPE in several chronic diseases. In September 2023, a team of researchers in Japan published a study ‘Serum Immunoglobulin G Level Reduction is a Predictor of Short-Term Improvement in Patients with Myasthenia Gravis Undergoing Plasmapheresis,’ in the journal Therapeutic Apheresis and Dialysis. The study investigated the serological factors in predicting symptom improvement in Myasthenia Gravis (MG) patients who underwent plasmapheresis and found that reduction in immunoglobulin G helps improve the symptoms of MG patients who underwent plasmapheresis.

Emergence of COVID-19 is fueling the therapeutic plasma exchange market expansion. Plasma exchange therapy effectively removes pro-inflammatory factors that are evident in patients with SARS-CoV-2 infection. Several studies have reported that plasmapheresis aids in improving survival in patients with severe COVID-19. One study ‘Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection’, published in October 2020, achieved zero mortality in patients with severe COVID-19 who received 5 sessions of plasmapheresis.

Regional Outlook

According to the latest therapeutic plasma exchange market analysis, North America held largest share in 2022. High prevalence of neurological disorders is fueling the market dynamics of the region. According to the study ‘Burden of Neurological Disorders Across the US from 1990-2017 A Global Burden of Disease Study’, published in November 2020, stroke (3.58 million DALYs), Alzheimer’s disease and other dementias (2.55 million DALYs), and migraine (2.40 million DALYs) were the most burdensome neurological disorders in the U.S. in terms of absolute number of DALYs.

Analysis of Key Players

Therapeutic plasma exchange manufacturers are offering advanced and efficient TPE machines with state-of-the-art technology to differentiate themselves from other companies. They are investing in research and development to improve TPE technology and increase their therapeutic plasma exchange market share.

Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, and Medica S.p.A. are major therapeutic plasma exchange companies.

Each of these players has been profiled in the therapeutic plasma exchange market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In May 2023, the Qatar Red Crescent Society (QRCS) introduced the plasmapheresis procedure at hospitals in Gaza
  • In July 2020, Sher-i-Kashmir Institute of Medical Sciences (SKIMS) in Jammu and Kashmir, India, installed sophisticated machinery for conducting plasmapheresis of COVID-19 patients

Therapeutic Plasma Exchange Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 1.5 Bn
Market Forecast Value in 2031 US$ 2.9 Bn
Growth Rate (CAGR) 7.5%
Forecast Period 2023 to 2031
Historical Data Available for 2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Disease Indication
    • Neurological Disorders
      • Chronic Inflammatory Demyelinating Polyneuropathy
      • Myasthenia Gravis
      • Multiple Sclerosis
      • Neuromyelitis Optica
      • Guillain-Barre Syndrome
    • Renal Disorders
      • Post-renal Transplant Rejection
      • Anti-glomerular Basement Membrane (GBM) Disease
      • Wegener's Granulomatosis
    • Hematology Disorders
      • Thrombotic Thrombocytopenic Purpura
      • Hemolytic Uremic Syndrome
      • Cryoglobulinemia
      • Multiple Myeloma
      • Metabolic Disorders
      • Homozygous Familial Hypercholesterolemia
      • Fulminant Wilson’s Disease
    • Others
  • End-user
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
Companies Profiled
  • Asahi Kasei Corporation
  • Baxter International, Inc.
  • Terumo Corporation
  • B. Braun SE
  • Fresenius Kabi AG
  • SB-Kawasumi Laboratories, Inc.
  • Haemonetics Corporation
  • Cerus Corporation
  • Charles River Laboratories
  • Medica S.p.A.
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the therapeutic plasma exchange market in 2022?

It was valued at US$ 1.5 Bn in 2022

How is the therapeutic plasma exchange business expected to grow by 2031?

It is projected to grow at a CAGR of 7.5% from 2023 to 2031

What are the key factors driving the demand for therapeutic plasma exchange?

Rise in prevalence of chronic diseases and R&D in therapeutic plasma exchange

Which end-user segment held the largest share in the therapeutic plasma exchange industry in 2022?

The hospitals end-user segment held the largest share in 2022

Which was the major region in the therapeutic plasma exchange landscape in 2022?

North America held largest share in 2022

Who are the key therapeutic plasma exchange manufacturers?

Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, and Medica S.p.A.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Therapeutic Plasma Exchange Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Therapeutic Plasma Exchange Market Analysis and Forecast, 2023–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Disease Indication

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Disease Indication, 2023–2031

            6.3.1. Neurological Disorders

                6.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                6.3.1.2. Myasthenia Gravis

                6.3.1.3. Multiple Sclerosis

                6.3.1.4. Neuromyelitis Optica

                6.3.1.5. Guillain-Barre Syndrome

            6.3.2. Renal Disorders

                6.3.2.1. Post-renal Transplant Rejection

                6.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                6.3.2.3. Wegener’s Granulomatosis

            6.3.3. Hematology Disorders

                6.3.3.1. Thrombotic Thrombocytopenic Purpura

                6.3.3.2. Hemolytic Uremic Syndrome

                6.3.3.3. Cryoglobulinemia

                6.3.3.4. Multiple Myeloma

                6.3.3.5. Metabolic Disorders

                6.3.3.6. Homozygous Familial Hypercholesterolemia

                6.3.3.7. Fulminant Wilson’s Disease

            6.3.4. Others

        6.4. Market Attractiveness Analysis, by Disease Indication

    7. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by End-user

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by End-user, 2023–2031

            7.3.1. Hospitals

            7.3.2. Specialty Clinics

            7.3.3. Ambulatory Surgical Centers

        7.4. Market Attractiveness Analysis, by End-user

    8. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2023–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Therapeutic Plasma Exchange Market Analysis and Forecast

        9.1. Introduction

        9.2. Key Findings

        9.3. Market Value Forecast, by Disease Indication, 2023–2031

            9.3.1. Neurological Disorders

                9.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                9.3.1.2. Myasthenia Gravis

                9.3.1.3. Multiple Sclerosis

                9.3.1.4. Neuromyelitis Optica

                9.3.1.5. Guillain-Barre Syndrome

            9.3.2. Renal Disorders

                9.3.2.1. Post-renal Transplant Rejection

                9.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                9.3.2.3. Wegener’s Granulomatosis

            9.3.3. Hematology Disorders

                9.3.3.1. Thrombotic Thrombocytopenic Purpura

                9.3.3.2. Hemolytic Uremic Syndrome

                9.3.3.3. Cryoglobulinemia

                9.3.3.4. Multiple Myeloma

                9.3.3.5. Metabolic Disorders

                9.3.3.6. Homozygous Familial Hypercholesterolemia

                9.3.3.7. Fulminant Wilson’s Disease

            9.3.4. Others

        9.4. Market Value Forecast, by End-user, 2023–2031

            9.4.1. Hospitals

            9.4.2. Specialty Clinics

            9.4.3. Ambulatory Surgical Centers

        9.5. Market Value Forecast, by Country, 2023–2031

            9.5.1. U.S.

            9.5.2. Canada

        9.6. Market Attractiveness Analysis

            9.6.1. By Disease Indication

            9.6.2. By End-user

            9.6.3. By Country

    10. Europe Therapeutic Plasma Exchange Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Disease Indication, 2023–2031

            10.3.1. Neurological Disorders

                10.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                10.3.1.2. Myasthenia Gravis

                10.3.1.3. Multiple Sclerosis

                10.3.1.4. Neuromyelitis Optica

                10.3.1.5. Guillain-Barre Syndrome

            10.3.2. Renal Disorders

                10.3.2.1. Post-renal Transplant Rejection

                10.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                10.3.2.3. Wegener’s Granulomatosis

            10.3.3. Hematology Disorders

                10.3.3.1. Thrombotic Thrombocytopenic Purpura

                10.3.3.2. Hemolytic Uremic Syndrome

                10.3.3.3. Cryoglobulinemia

                10.3.3.4. Multiple Myeloma

                10.3.3.5. Metabolic Disorders

                10.3.3.6. Homozygous Familial Hypercholesterolemia

                10.3.3.7. Fulminant Wilson’s Disease

            10.3.4. Others

        10.4. Market Value Forecast, by End-user, 2023–2031

            10.4.1. Hospitals

            10.4.2. Specialty Clinics

            10.4.3. Ambulatory Surgical Centers

            10.4.4. Others

        10.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            10.5.1. Germany

            10.5.2. U.K.

            10.5.3. France

            10.5.4. Italy

            10.5.5. Spain

            10.5.6. Rest of Europe

        10.6. Market Attractiveness Analysis

            10.6.1. By Disease Indication

            10.6.2. By End-user

            10.6.3. By Country/Sub-region

    11. Asia Pacific Therapeutic Plasma Exchange Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Disease Indication, 2023–2031

            11.3.1. Neurological Disorders

                11.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                11.3.1.2. Myasthenia Gravis

                11.3.1.3. Multiple Sclerosis

                11.3.1.4. Neuromyelitis Optica

                11.3.1.5. Guillain-Barre Syndrome

            11.3.2. Renal Disorders

                11.3.2.1. Post-renal Transplant Rejection

                11.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                11.3.2.3. Wegener’s Granulomatosis

            11.3.3. Hematology Disorders

                11.3.3.1. Thrombotic Thrombocytopenic Purpura

                11.3.3.2. Hemolytic Uremic Syndrome

                11.3.3.3. Cryoglobulinemia

                11.3.3.4. Multiple Myeloma

                11.3.3.5. Metabolic Disorders

                11.3.3.6. Homozygous Familial Hypercholesterolemia

                11.3.3.7. Fulminant Wilson’s Disease

            11.3.4. Others

        11.4. Market Value Forecast, by End-user, 2023–2031

            11.4.1. Hospitals

            11.4.2. Specialty Clinics

            11.4.3. Ambulatory Surgical Centers

            11.4.4. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.5.1. China

            11.5.2. Japan

            11.5.3. India

            11.5.4. Australia & New Zealand

            11.5.5. Rest of Asia Pacific

        11.6. Market Attractiveness Analysis

            11.6.1. By Disease Indication

            11.6.2. By End-user

            11.6.3. By Country/Sub-region

    12. Latin America Therapeutic Plasma Exchange Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Disease Indication, 2023–2031

            12.3.1. Neurological Disorders

                12.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                12.3.1.2. Myasthenia Gravis

                12.3.1.3. Multiple Sclerosis

                12.3.1.4. Neuromyelitis Optica

                12.3.1.5. Guillain-Barre Syndrome

            12.3.2. Renal Disorders

                12.3.2.1. Post-renal Transplant Rejection

                12.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                12.3.2.3. Wegener’s Granulomatosis

            12.3.3. Hematology Disorders

                12.3.3.1. Thrombotic Thrombocytopenic Purpura

                12.3.3.2. Hemolytic Uremic Syndrome

                12.3.3.3. Cryoglobulinemia

                12.3.3.4. Multiple Myeloma

                12.3.3.5. Metabolic Disorders

                12.3.3.6. Homozygous Familial Hypercholesterolemia

                12.3.3.7. Fulminant Wilson’s Disease

            12.3.4. Others

        12.4. Market Value Forecast, by End-user, 2023–2031

            12.4.1. Hospitals

            12.4.2. Specialty Clinics

            12.4.3. Ambulatory Surgical Centers

            12.4.4. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.5.1. Brazil

            12.5.2. Mexico

            12.5.3. Rest of Latin America

        12.6. Market Attractiveness Analysis

            12.6.1. By Disease Indication

            12.6.2. By End-user

            12.6.3. By Country/Sub-region

    13. Middle East & Africa Therapeutic Plasma Exchange Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Disease Indication, 2023–2031

            13.3.1. Neurological Disorders

                13.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy

                13.3.1.2. Myasthenia Gravis

                13.3.1.3. Multiple Sclerosis

                13.3.1.4. Neuromyelitis Optica

                13.3.1.5. Guillain-Barre Syndrome

            13.3.2. Renal Disorders

                13.3.2.1. Post-renal Transplant Rejection

                13.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease

                13.3.2.3. Wegener’s Granulomatosis

            13.3.3. Hematology Disorders

                13.3.3.1. Thrombotic Thrombocytopenic Purpura

                13.3.3.2. Hemolytic Uremic Syndrome

                13.3.3.3. Cryoglobulinemia

                13.3.3.4. Multiple Myeloma

                13.3.3.5. Metabolic Disorders

                13.3.3.6. Homozygous Familial Hypercholesterolemia

                13.3.3.7. Fulminant Wilson’s Disease

            13.3.4. Others

        13.4. Market Value Forecast, by End-user, 2023–2031

            13.4.1. Hospitals

            13.4.2. Specialty Clinics

            13.4.3. Ambulatory Surgical Centers

            13.4.4. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.5.1. GCC Countries

            13.5.2. South Africa

            13.5.3. Rest of Middle East & Africa

        13.6. Market Attractiveness Analysis

            13.6.1. By Disease Indication

            13.6.2. By End-user

            13.6.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Asahi Kasei Corporation

                14.3.1.1. Company Overview

                14.3.1.2. Product Portfolio

                14.3.1.3. SWOT Analysis

                14.3.1.4. Financial Overview

                14.3.1.5. Strategic Overview

            14.3.2. Baxter International, Inc.

                14.3.2.1. Company Overview

                14.3.2.2. Product Portfolio

                14.3.2.3. SWOT Analysis

                14.3.2.4. Financial Overview

                14.3.2.5. Strategic Overview

            14.3.3. Terumo Corporation

                14.3.3.1. Company Overview

                14.3.3.2. Product Portfolio

                14.3.3.3. SWOT Analysis

                14.3.3.4. Financial Overview

                14.3.3.5. Strategic Overview

            14.3.4. B. Braun SE

                14.3.4.1. Company Overview

                14.3.4.2. Product Portfolio

                14.3.4.3. SWOT Analysis

                14.3.4.4. Financial Overview

                14.3.4.5. Strategic Overview

            14.3.5. Fresenius Kabi AG

                14.3.5.1. Company Overview

                14.3.5.2. Product Portfolio

                14.3.5.3. SWOT Analysis

                14.3.5.4. Financial Overview

                14.3.5.5. Strategic Overview

            14.3.6. SB-Kawasumi Laboratories, Inc.

                14.3.6.1. Company Overview

                14.3.6.2. Product Portfolio

                14.3.6.3. SWOT Analysis

                14.3.6.4. Financial Overview

                14.3.6.5. Strategic Overview

            14.3.7. Haemonetics Corporation

                14.3.7.1. Company Overview

                14.3.7.2. Product Portfolio

                14.3.7.3. SWOT Analysis

                14.3.7.4. Financial Overview

                14.3.7.5. Strategic Overview

            14.3.8. Cerus Corporation

                14.3.8.1. Company Overview

                14.3.8.2. Product Portfolio

                14.3.8.3. SWOT Analysis

                14.3.8.4. Financial Overview

                14.3.8.5. Strategic Overview

            14.3.9. Charles River Laboratories

                14.3.9.1. Company Overview

                14.3.9.2. Product Portfolio

                14.3.9.3. SWOT Analysis

                14.3.9.4. Financial Overview

                14.3.9.5. Strategic Overview

            14.3.10. Medica S.p.A.

                14.3.10.1. Company Overview

                14.3.10.2. Product Portfolio

                14.3.10.3. SWOT Analysis

                14.3.10.4. Financial Overview

                14.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 02: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    Table 03: Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Region, 2023–2031

    Table 04: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country, 2023–2031

    Table 05: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 06: North America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    Table 07: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 08: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 09: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    Table 10: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 11: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 12: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    Table 13: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 14: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 15: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    Table 16: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

    Table 17: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2031

    Table 18: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, by End-user, 2023–2031

    List of Figures

    Figure 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031

    Figure 02: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Disease Indication, 2022

    Figure 03: Global Therapeutic Plasma Exchange Market Value Share, by Disease Indication, 2022

    Figure 04: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by End-user, 2022

    Figure 05: Global Therapeutic Plasma Exchange Market Value Share, by End-user, 2022

    Figure 06: Global Therapeutic Plasma Exchange Market Value Share, by Region, 2022

    Figure 07: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2023–2031

    Figure 08: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 09: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022-2031

    Figure 10: Global Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 11: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022-2031

    Figure 12: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Region, 2023 and 2031

    Figure 13: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Region, 2022-2031

    Figure 14: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 15: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country, 2023–2031

    Figure 16: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Country, 2023 and 2031

    Figure 17: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 18: North America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 19: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031

    Figure 20: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 21: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 22: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 23: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 24: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 25: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 26: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031

    Figure 27: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 28: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 29: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 30: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 31: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 32: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 33: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031

    Figure 34: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 35: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 36: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 37: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 38: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 39: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 40: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031

    Figure 41: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 42: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

    Figure 43: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 44: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

    Figure 45: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2023 and 2031

    Figure 46: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2023 and 2031

    Figure 47: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication, 2022–2031

    Figure 48: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved